Lin BioScience, Inc. (TPEX:6696)

Market Cap	32.84B +217.6%
Revenue (ttm)	n/a
Net Income	-1.02B
EPS	-12.79
Shares Out	82.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	896,891
Average Volume	836,810
Open	399.50
Previous Close	401.50
Day's Range	385.50 - 400.50
52-Week Range	91.50 - 502.00
Beta	-0.03
RSI	53.37
Earnings Date	Apr 27, 2026

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Zhengqi Wang
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6696